VGXI New Manufacturing Facility Achieves Construction Milestones In Advance of 2022 Operational Date

Specialized GMP contract manufacturer VGXI, Inc. announced multiple construction milestones have been reached for its new headquarters and expanded manufacturing facility in Conroe, TX.

New Manufacturing Facility

The Woodlands, TX – VGXI, Inc., an industry leading contract developer and manufacturer (CDMO) for nucleic acid biopharmaceuticals including DNA vaccines and gene therapies, announced that its new headquarters and manufacturing facility located at Deison Technology Park in Conroe, TX is now dried-in with multiple stages of equipment arriving for installation. Only 5 months since the final steel beam was set in place for the building in April, 2021, the dry-in date marks a significant milestone for the 120,000 SQ FT building, allowing interior progress to speed forward regardless of weather conditions.

Now that the entire facility exterior is complete, major mechanical equipment including air handlers, process chillers, and the sterile water filtration system components are arriving and being installed. In addition, full site backup generation will be complete this month, enabling uninterrupted power to the facility, independent of the electrical grid when required. The aggressive construction schedule will continue over the next several months with focus on interior mechanicals, installation of cleanroom suites and manufacturing equipment, and building finishes.

“The need for highly skilled production of DNA and RNA medicines is rapidly expanding,” stated VGXI President and CEO Mr. Young Park. “With this new purpose-built facility our company is perfectly positioned to leverage decades of expertise and robust, scalable DNA manufacturing technologies to meet these demands for both current and future clients.”

The new VGXI headquarters offers multiple independent manufacturing suites with increased fermentation capacities up to the 1500L scale. Orders are now being taken for production slots starting in April 2022.

BE&K Building Group is the design-builder of record, in partnership with architectural partner Hanbury and engineering partner Hipp Engineering & Consulting.


VGXI, Inc., with 20 years of experience, is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a GeneOne company.


GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II).

VGXI, Inc., a GeneOne company located in The Woodlands, Texas, is the global leading CDMO for cGMP DNA plasmid manufacture.

For more information, visit


BE&K Building Group is an integrated construction services company serving pharmaceutical + biotechnology, advanced manufacturing + distribution, healthcare, and additional select commercial markets for more than 50 years. The company provides services nationwide through its operations in Houston, Chicago, and the Carolinas. A full range of services is offered including design-build, construction management, preconstruction, and client advisory/consulting. Additional information is available at


Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Click here to view the official release on PRWeb.

Media Contacts:

Christy Franco, Ph.D.

Sr. Manager, Business Development

Click Here to Contact

Don’t forget to share this post!